key: cord-0763212-t9im00d1 authors: Antoine-Reid, Thessicar; Malone, James; Maris, Alexander S; White-Abell, Jill; Schmitz, Jonathan E title: Cross-Comparison of a Chemiluminescent Platform and a Commercial Receptor Binding Domain-Based ELISA Assay for Detecting SARS-CoV-2 IgG date: 2020-08-04 journal: J Appl Lab Med DOI: 10.1093/jalm/jfaa133 sha: 2c85f08d27c8a8a7dd4eabd75a7e83521e702e80 doc_id: 763212 cord_uid: t9im00d1 nan The COVID-19 pandemic has rapidly emerged as a defining public-health crisis of the 21st century (1) . Not surprisingly, laboratory testing has played a vital role in diagnosing cases and tracking prevalence. Among different techniques, serologic testing detects the body's antibody response to infection, as opposed to direct detection of the virus (2) . Serodiagnostic approaches remain dynamic, however, with a growing number of products that differ in terms of methodology (lateral flow, ELISA, chemiluminescent), performance setting (central lab, point-of-care), antigenic target (nucleocapsid, total spike protein-S1, receptor binding domain-RBD), instrumentation requirements, and regulatory status. In addition to products with research use only (RUO) status, serology tests with FDA-approval carry only emergency use authorization (EUA), as the pandemic has precluded pre-marketing trials. A further complication is how results should be acted upon clinically, as it remains unresolved whether the presence of SARS-CoV-2 antibodies -even when detected accurately -protect against reinfection. Beyond clinical significance, additional questions surround the analytic performance of the tests themselves. Concerns have been raised regarding unacceptably high rates of falsepositivity for some assays, potentially due to cross-reactivity from other coronaviruses (3) . Local epidemiology presents more challenges, as high-specificity techniques can nevertheless demonstrate poor positive predictive value in low-prevalence settings (4) . Among the first COVID-19 serodiagnostics to receive EUA was the Abbott Architect IgG assay. This automated, chemiluminescent technology has demonstrated high sensitivity and specificity for the analysis of serum/plasma from PCR-diagnosed patients, along with pre-pandemic specimens (5, 6) . In the context of on-site serology implementation, we evaluated the performance of the Architect together with a second candidate assay: the GenScript SARS-CoV-2 Spike S1-RBD IgG ELISA, an RUO-methodology that would require local validation to meet CLIA/FDA requirements. Parallel Architect and ELISA analyses were conducted for several adult-cohorts (with IRB approval). To assess specificity, cryobanked pre-pandemic specimens were employed: 230 serum (from activating serum separator tubes) and 238 plasma (from spun EDTA tubes). To assess sensitivity, specimens were obtained from unique SARS-CoV-2-PCR-positive subjects ≥17 days post symptom-onset (5). These included 21 paired plasma/serum specimens from recovered donors who never required hospitalization, as well as 25 plasma-only specimens from hospitalized patients (derivatives of care). 31 additional plasma samples were analyzed from other unique hospitalized patients, but these were considered separately due to <17 days from symptom-onset. The results of these experiments are summarized in Figure 1 for one inpatient plasma specimen, all ELISA false-negative results (either threshold) occurred with non-hospitalized donors. In this context, the above sensitivity-calculations for serum are qualified by the fact that these specimens were only available from non-hospitalized donors. As a result, we cannot make any rigorous conclusions on whether plasma or serum might provide better sensitivity data for the ELISA. Finally, analyses were performed on separate plasma specimens from 31 inpatients <17 days post-symptomatic, where seropositivity is less predictable, yielding detection-rates of 24/31 by Architect, 18/31 by ELISA-threshold #1, and 16/31 by ELISAthreshold #2. Overall, these data further support the high sensitivity and specificity of the Architect assay, including for specimens with ELISA cross-reactivity. Additional studies are needed to clarify how observable seropositivity for PCR-confirmed/recovered individuals varies with disease severity (both via Architect and in general). By contrast, our results demonstrate less favorable performance characteristics for GenScript's RBD-based IgG ELISA. In particular, institutions considering validation/implementation of this kit (either per the manufacturer's instructions or with modified protocols/thresholds) may need to consider local COVID-19 prevalence to avoid high falsepositivity. Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. T.E. Antoine-Reid, statistical analysis, administrative support; J.E. Malone, statistical analysis; J.E. Schmitz, statistical analysis. China Medical Treatment Expert Group for, Clinical Characteristics of Coronavirus Disease 2019 in China Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19 Clinical Performance of Two SARS-CoV-2 Serologic Assays Two-by-two agreement tables are presented for analysis of serum and plasma, on both the Architect IgG Assay, the GenScript IgG Assay with positivity threshold #1 (see text), and the GenScript IgG Assay with positivity threshold #2. The Reference Comparator represents PCR-defined SARS-CoV-2 infection with ≥17 days postsymptom onset (for positive specimens) and pre-pandemic origins (for negative specimens). For positive specimens, both non-hospitalized and hospitalized sources are combined in the tables. In addition to the number of patients/specimens that fall within each category, each square summarizes parenthetically the median raw-signal value (S/C for Architect, OD450 for GenScript) for that respective group or -when a No authors declared any potential conflicts of interest.